For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

TOP1 is the target of topotecan, which was approved in 1997 by the U.S. Food and Drug Administration (FDA) to treat relapsed ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

"For healthcare providers, these findings suggest that anti-obesity medications may offer dual benefits," one doctor reports today.

Obesity has been declared a disease by WHO. It is associated not only with heart disease, diabetes, stroke, gallstones, ...

Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide ... at ...

Real-World Adherence to Repeat Testing for Stool-Based Non-Invasive Colorectal Cancer Screening Tests Among Individuals ... PhD, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With ...